Download Now - The Burrill Report

More documents

Recommendations

Info

THIRD QUARTER STATISTICSThe Burrill Report❱❱ (continued)Q3 2012 Select Pharma/Biotech Alliances With Academia And NonprofitsCOMPANY ACADEMIA/ NONPROFIT PRINCIPAL FOCUS TERMSPerkinElmerTakeda Pharmaceutical(Japan)Astex PharmaceuticalsMassachusetts GeneralHospitalBritish Columbia CancerAgency (Canada)Cancer Research Technology(United Kingdom)Tumor profilingCancer researchEpigenetic drugCollaboration to develop a sequencing informatics system forprofiling the genetic changes in tumors for use in advanced cancerresearch.Research partnership to discover and develop cancer targets basedon gene analysis. The deal is the first for Takeda’s new ShonanIncubation Laboratories program, under which the pharma invitesdistinguished researchers from external institutions to lead projectsat the Shonan Research Center.Collaboration to discover and develop drug candidates targetingan undisclosed epigenetic target in a blood cancer with high unmetmedical need, combining Astex’s fragment-based drug discoveryplatform and epigenetic drug development experience withthe expertise in blood cancer biology at The Institute of CancerResearch and proven success in drug discovery at the CancerResearch UK Cancer Therapeutics Unit at the ICR.AstraZeneca Broad Institute Infectious disease Collaboration to identify new chemical compounds targetingbacterial and viral infections that could speed the development ofnew antibacterial and antiviral drugs. The chemical library, createdat the Broad Institute, comprises 100,000 customized moleculesknown as Diversity-Oriented Synthesis (DOS) compounds.Screening and hit-to-lead chemistry will take place in the Broad’sChemical Biology Platform and AstraZeneca will optimize, developand commercialize potential compounds from identified, highqualityleads.Abbott, AstraZeneca,Boehringer Ingelheim,Bristol-Myers Squibb,Eli Lilly and Company,GlaxoSmithKline, Johnson& Johnson, Pfizer,Genentech, and SanofiSanofi (France)TransCelerate BioPharmaGlobal Alliance for TB DrugDevelopmentSolving R&DchallengesTB drugdevelopmentBristol-Myers Squibb Vanderbilt University Parkinson’stherapiesTen biopharmas form a non-profit organization to accelerate thedevelopment of new medicines called TransCelerate BioPharma,to identify and solve common drug development challengeswith the end goals of improving the quality of clinical studies andbringing new medicines to patients faster. Ech of the ten foundingcompanies will combine financial and other resources, includingpersonnel, to solve industry-wide challenges in a collaborativeenvironment.Research collaboration agreement to accelerate the discovery anddevelopment of novel compounds against tuberculosis. Sanofiand TB Alliance will collaborate to further optimize and developseveral novel compounds in Sanofi’s library that have demonstratedactivity against Mycobacterium tuberculosis, the bacterium thatcauses TB.Partnership to discover, develop, and commercialize positiveallosteric modulators of mGluR4 to treat Parkinson’s disease. Theuniversity’s Center for Neuroscience Drug Discovery will receivean upfront payment and multi-year research funding from BMS toidentify drug candidates from the center’s preclinical mGluR4 PAMprogram; plus is eligible for milestones and royalties. BMS will haverights to develop and commercialize products resulting from the deal.nNovember 2012 22
The Burrill ReportSEPTEMBER STATISTICSFinancings: Early-stage Therapeutic Financings Pull RankFunding is available for innovative startupsVenture capitalistswant companies tohave differentiatedproducts forunmet needs thattarget a definedpatient population.They also want amanagement teamof businessmenand scientists thathave already beensuccessful movingother companiesforward.BY MARIE DAGHLIANAlthough the financing outlook forearly-stage biotech firms remainsdifficult, they are getting funded, especiallyif they have a novel technologythat can result in breakthrough treatmentsfor unmet needs. Of the $307 millionraised by U.S. privately held therapeuticbiotechs during September, $121million, or 39.4 percent, were raised infirst round venture financings or seriesA rounds.Series A financings of therapeuticsdevelopers accounted for 17.6 percent ofthe total $689 million raised in financingsof privately-held U.S. life sciencescompanies in September, includingtherapeutics, diagnostics, tools/technology,medical devices, and digital healthand healthcare IT.Even with a dwindling number ofventure firms willing to invest in earlystagedeals, the appetite to build companieshas not gone away. However, venturecapitalists want companies to havedifferentiated products for unmet needsthat target a defined patient population.They also want to build companies witha management team of businessmen andscientists that have already been successfulmoving other companies forward.Third Rock Ventures exemplifiesa new breed of venture firm that islaunching new companies, sometimeson its own, but more often with otherinvestors that often include Big Pharma.In September, Third Rock launched SanFrancisco-based MyoKardia with a $38million series A financing of the company.MyoKardia uses a genetically targetedapproach to develop novel smallmolecule therapeutics for patients withfrom genetic heart disease. Its first programsfocus on hypertrophic and dilatedcardiomyopathy, which togetherafflict approximately 1 million peoplein the United States, and for which nonovel therapeutics have been brought tomarket in over a decade.“The last decade has been challengingfor those pursuing novel therapeuticsin the cardiovascular space, in partbecause most treatments target symptomsfar downstream of the root cause,”says Leslie Leinwand, one of MyoKardia’sco-founders and a professor ofmolecular, cellular, and developmentalbiology at the University of Colorado.“MyoKardia’s approach addresses thischallenge head on by employing geneticsto more precisely define the diseaseand ‘who we want to treat,’ and by employingcutting-edge muscle biochemistryand a novel platform to determine‘how we want to treat.’”Though the company’s inititial targetsare genetic cardiomyopathies,Leinwand said this could be a noveland tractable therapeutic discovery approachto even larger diseases, such asheart failure.MPM Capital led a $23 million seriesA financing round for SelexysPharmaceuticals, which is developinga treatment for sickle cell disease. Thefinancing closed concurrent with theannouncement that the Oklahoma Citybasedbiotech had entered into an agreementwith Novartis potentially worthup to $665 million that includes an optionfor Novartis to buy the companyand its lead asset, which is completed aphase 1 safety study. The option is triggeredfollowing the successful completionof a phase 2 study. Selexys’ leadcompound SelG1 is a first-in-class therapeuticapproach for treating vasoocclusivecrisis, a painful chronic occurrencethat requires frequent hospitalizationfor sickle cell patients.“Vaso-occulsive crises represent asignificant healthcare problem for sicklecell disease patients, and we wereimpressed by the early data for SelG1and the quality of the Selexys team,”says Todd Foley, a managing director ofMPM Capital who has joined the boardof Selexys. “We are pleased to be a partof this successful financing structure,and I look forward to working closelywith Selexys.”nNovember 2012 23
Page 2 and 3: The Burrill ReportThe Burrill Repor
Page 5: The Burrill ReportThe Risk and Rewa
Page 10 and 11: The Burrill ReportTHIRD QUARTER STA
Page 12 and 13: THIRD QUARTER STATISTICSThe Burrill
Page 24 and 25: SEPTEMBER STATISTICSThe Burrill Rep
Page 28: SEPTEMBER STATISTICSThe Burrill Rep
Page 39 and 40: PIPELINEThe Burrill Report❱❱ (c
Page 45: PIPELINEThe Burrill Report❱❱ (c
Page 48 and 49: PIPELINEThe Burrill ReportUpcoming
Page 50 and 51: INDICESThe Burrill ReportBurrill Bi

Download Now - The Burrill Report

Create successful ePaper yourself

Delete template?

Save as template?